Skip to main content
Subscribe
  • Sign Up Free
  • Login
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Blogs
    • AI
    • Deals
    • Layoff Tracker
    • HIMSS 2023
  • Opinion
    • Breaking Bias
    • Commentaries
    • Letters
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • Best Places to Work in Healthcare
    • Excellence in Governance
    • Health Care Hall of Fame
    • Healthcare Marketing Impact Awards
    • Top 25 Emerging Leaders
    • Top Innovators
    • Diversity in Healthcare
      • - Luminaries
      • - Top 25 Diversity Leaders
      • - Leaders to Watch
    • Women in Healthcare
      • - Luminaries
      • - Top 25 Women Leaders
      • - Women to Watch
    • Digital Health Transformation Summit
    • ESG: The Implementation Imperative Summit
    • Leadership Symposium
    • Social Determinants of Health Symposium
    • Women Leaders in Healthcare Conference
    • Best Places to Work Awards Gala
    • Health Care Hall of Fame Gala
    • Top 25 Diversity Leaders Gala
    • Top 25 Women Leaders Gala
    • - Hospital of the Future
    • - Value Based Care
    • - Hospital at Home
    • - Workplace of the Future
    • - AI and Digital Health
    • - Future of Staffing
    • - Hospital of the Future (Fall)
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Sponsored Video Series - One on One
    • Sponsored Video Series - Checking In with Dan Peres
  • Data & Insights
    • Data & Insights Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
MENU
Breadcrumb
  1. Home
  2. Government
April 29, 2015 12:00 AM

New medical innovation bill draft boosts NIH funding

Darius Tahir
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print

    WASHINGTON—A new draft of House legislation that creates significant new regulatory leeway for drug and device companies now includes more funding for the National Institutes of Health. The revised draft represents a compromise with Democrats who withdrew support for the initial bill.

    Leaders of the House Energy & Commerce Committee are circulating a new “discussion draft” of the 21st Century Cures bill that would raise NIH funding to $31.8 billion in fiscal 2016 and to $34.85 billion in fiscal 2018. Congress appropriated $30.3 billion for the NIH in fiscal 2015, and President Barack Obama requested (PDF) $31.3 billion for fiscal 2016.

    The bill would also create an NIH Innovation Fund of roughly $2 billion per year between fiscal years 2016 and 2020. The fund would support precision medicine, young emerging scientists and other unidentified sources of medical innovation.

    Research!America, an advocacy group promoting healthcare research, said it was “thrilled” by the new version of the bill but warned that the final legislation must allow the NIH to decide how to allocate the dollars.

    But consumer watchdog Public Citizen called the NIH funding boost a horse trade “providing perks to the pharmaceutical and medical device industries to approve medications and devices faster based on weaker evidence.”

    The bill would significantly revise regulations governing the Food and Drug Administration's oversight of the drug, device and software sectors.

    Pharmaceutical Research and Manufacturers of America, the industry's trade group, issued a statement applauding the House committee for its work.

    The drug industry would benefit from the bill in several ways. Perhaps most significantly would be the proposed legislation's enhanced consideration of “real-world evidence.” Manufacturers would be able to expand a drug's indications based on observational data or registries indicating how it performs in the field. Critics say the provision would lead the government to endorse drugs for new uses without adequate testing for safety and efficacy.

    The FDA would also be required to develop more surrogate endpoints to allow shorter clinical trials. For example, the FDA might accept evidence that a new cancer drug effectively shrinks tumors rather than requiring a longer and more expensive clinical trial showing reduced mortality.

    The device industry would also benefit. A proposed “breakthrough device” program would provide a faster path to market for devices that might substantially raise the standard of care.

    An additional provisional section would expand the FDA's “humanitarian device exemption” for products that treat rare diseases. Under current law, a device treating a disease affecting fewer than 4,000 patients per year receives less regulatory scrutiny. The provisional section would raise that cap to 8,000.

    Dr. Margaret Hamburg, who stepped down as the FDA commissioner last month, has said the bill's approach is misguided. "Shortening review times is not going to create the scientific understanding and the research and development that needs to be done to translate exciting opportunities in science into new products," Hamburg told Modern Healthcare in a recent interview. “That is the wrong mechanism to achieve that goal.”

    FDA officials told lawmakers during a Senate committee hearing Tuesday that the agency is already overburdened and underfunded, compromising its ability to efficiently evaluate new and modified drugs and devices.

    The draft bill, however, calls for the FDA to issue new guidance in areas ranging from the use of Bayesian statistics in clinical trials to precision medicine, and would require the agency to convene seven public meetings or workshops. The word “guidance” occurs 98 times in the 199-page bill. But, at the moment, there are no specific additional appropriations for the agency.

    The legislation would also revise the regulatory categories for healthcare software. Any technology falling under the category of “health software,” which includes administrative and other software deemed low-risk, would be exempt from FDA scrutiny.

    Some clinical decision-support software, which guides clinicians with alerts or alarms, would fall outside that exemption.

    It's unclear, however, how much clarity the bill would offer developers of such software, said Bradley Thompson, a health information technology expert with the law firm Epstein Becker Green.

    The bill “gives FDA quite a bit of latitude to decide what (clinical decision-support software) to regulate,” Thompson said. “But the original purpose of this legislation was to more clearly define the dividing line between regulated and unregulated software.”

    The health IT community also expected the legislation to tackle the lackluster ability of health IT systems to exchange data. The draft bill includes a placeholder for interoperability guidance but no details.

    “We have no doubt it will be part of the package before it is formally introduced,” said Dan Haley, vice president of government and regulatory affairs at electronic health-record vendor Athenahealth.

    The bill includes a similar placeholder for telehealth. That industry has lobbied aggressively for legislation to create a distinct Medicare billing code for remote-patient monitoring.

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    congress prescription drugs
    PBMs, Big Pharma face off in House hearing
    Biden COVID copy_i_i.jpg
    Biden administration asks employers to help more workers who lose Medicaid
    Most Popular
    1
    Centene to lay off 2,000 workers
    2
    How health systems are battling price-gouging allegations
    3
    Senate advances bill to temporarily aid hospitals, health centers
    4
    Elevance, Blue Cross Louisiana halt $2.5B proposed deal
    5
    Tower Health to sell urgent care centers, close others
    Sponsored Content
    Modern Healthcare Alert: Sign up for this breaking news email to be kept in the loop as urgent healthcare business news unfolds.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Help Center
    • Advertise with Us
    • Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2023. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Blogs
      • AI
      • Deals
      • Layoff Tracker
      • HIMSS 2023
    • Opinion
      • Breaking Bias
      • Commentaries
      • Letters
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • Best Places to Work in Healthcare
        • Excellence in Governance
        • Health Care Hall of Fame
        • Healthcare Marketing Impact Awards
        • Top 25 Emerging Leaders
        • Top Innovators
        • Diversity in Healthcare
          • - Luminaries
          • - Top 25 Diversity Leaders
          • - Leaders to Watch
        • Women in Healthcare
          • - Luminaries
          • - Top 25 Women Leaders
          • - Women to Watch
      • Conferences
        • Digital Health Transformation Summit
        • ESG: The Implementation Imperative Summit
        • Leadership Symposium
        • Social Determinants of Health Symposium
        • Women Leaders in Healthcare Conference
      • Galas
        • Best Places to Work Awards Gala
        • Health Care Hall of Fame Gala
        • Top 25 Diversity Leaders Gala
        • Top 25 Women Leaders Gala
      • Virtual Briefings
        • - Hospital of the Future
        • - Value Based Care
        • - Hospital at Home
        • - Workplace of the Future
        • - AI and Digital Health
        • - Future of Staffing
        • - Hospital of the Future (Fall)
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Sponsored Video Series - One on One
      • Sponsored Video Series - Checking In with Dan Peres
    • Data & Insights
      • Data & Insights Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing